Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497470 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
A Phase 1 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01497470 is a Phase 1 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 36 participants.
The verdict
NCT01497470, a Phase 1 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standard administered chemotherapy) and will measure custirsen blood levels in this cancer population. Finally, the study will evaluate the safety and tolerability of adding custirsen to the standard paclitaxel/carboplatin chemotherapy.
Interventions
- DRUG Custirsen, paclitaxel and carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497470
The ClinicalTrials.gov registry entry for NCT01497470 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Custirsen, paclitaxel and carboplatin is the first listed.
NCT01497470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497470 about?
NCT01497470 is a clinical study titled "A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen". The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standar...
What is the current status of trial NCT01497470?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-04. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01497470?
The interventions under investigation include: Custirsen, paclitaxel and carboplatin (DRUG).
Who is sponsoring clinical trial NCT01497470?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.